Rigel Pharmaceuticals Appoints New Chief Medical Officer, Former CMO Departs
RIGL has more than doubled off its 52-week low of $18.24.
Summary
Rigel Pharmaceuticals announced a leadership change in its medical department, with Dr. Alison L. Hannah appointed as the new Executive Vice President and Chief Medical Officer, succeeding Dr. Lisa Rojkjaer.
Key Events · Executive and Board Changes · RIGL
-
Chief Medical Officer Change
Dr. Lisa Rojkjaer ceased serving as Executive Vice President and Chief Medical Officer of the Company, effective June 25, 2026.
-
New CMO Appointed
Dr. Alison L. Hannah was appointed Executive Vice President and Chief Medical Officer, effective July 1, 2026.
-
Board Resignation
Dr. Hannah resigned from the Company's Board of Directors, effective July 1, 2026, concurrent with her appointment as CMO.
Analysis · RIGL · Life Sciences
This 8-K reports a significant executive transition for Rigel Pharmaceuticals. The departure of the previous Chief Medical Officer, Dr. Lisa Rojkjaer, and the immediate appointment of Dr. Alison L. Hannah, who was already a member of the company's Board of Directors, indicates a planned leadership change. For a life sciences company, the Chief Medical Officer role is critical for clinical development, regulatory strategy, and pipeline execution. Dr. Hannah's prior experience as a board member and in pharmaceutical development suggests a focus on continuity and strategic alignment, especially following recent major events like the VEPPANU licensing agreement.
At the time of this filing, RIGL was trading at $38.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $708.4M. The 52-week trading range was $18.24 to $52.24. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.